E2O 19th meeting 20211103

Welcome

@Daniel Karlsson

• DO NOT FORGET TO RECORD!

Conflicts of interest

@Daniel Karlsson

Discussion Phase 1 dataset for migration trial

57 min

@Jim Campbell

@Former user (Deleted)

@Daniel Karlsson

• Review of progress with conversion file for UK labs

• Modelling issues suggested by classification of Phase 1 migration set 

• Followup on issues from last meeting:

  • Timed specimens shall be identified by instance time stamp of acquisition 

  • 24 hour urine testing deferred to committee deliberation

• Red cell indices such as Mean corpuscular volume. Representation of averages (or any aggregation) has not yet been finally agreed on,proceed with proposed model

• Anti-mitocondrial antobody pattern, Leukocyte ALP → items deferred to Observables deliberation

• Agglutination test. Property = Presence, , Technique = Latex agglutination

• Titre. How to represent titre in relation to presence and quantity concentration; deferred to committee

• Von Willebrand factor activity - likely a process observable and out of scope.

• Produce an OWL file based on decisions made and compare hierarchy of reclassified Observables to Evaluation procedures.

2021-11-03:

• @Jim Campbell presented work since last time.

• DK: additional, the differences found between the Evalualtion procedure hierarchy and the E2O Observable hierarchy have highlighted issues with the Evaluation procedure hierarchy.

• Discussion about future progress of E2O

• UK current decision is to use Procedures in the context of ordering

  • There would in the UK content not be duplicates between "ordering" and "result" concepts.

• Keeping two hierarchies with essentially the same meaning introduces maintenance challenges

• There would be modeling solutions to keep hierarchies in sync, IFF it is possible to write clear guidance on when to use which hierarchy

Next meeting 

2 min

@Daniel Karlsson

AOB

1 min

@Daniel Karlsson